In a lung cancer model, the combination of ERRFI1 knockdown (shERRFI1) and anti-PD1 (α-PD1) therapy significantly reduced tumor burden (p < 0.0001) and improved survival rates, demonstrating a synergistic effect compared to monotherapy or the control group (Figures 7A–D). This evidence concerns the gene ERRFI1 and lung carcinoma.